Kotani, K and Serban, M-C and Penson, P and Lippi, G (2016) Evidence-based assessment of lipoprotein(a) as a risk biomarker for cardiovascular diseases – some answers and still many questions. Critical Reviews in Clinical Laboratory Sciences, 53 (6). pp. 370-378. ISSN 1549-781X (Accepted)
Revised)CRCLS)Lipoprotein(a) review.pdf - Accepted Version
Restricted to Repository staff only until 26 June 2017.
The present article is aimed to outline the current state of knowledge regarding the effects of lipoprotein(a) (Lp(a)) on cardiovascular disease (CVD) risk by summarizing the recent results of studies, meta-analyses and systematic reviews. The literature supports the predictive value of Lp(a) on CVD outcomes, although the effect size is modest. Lp(a) would also appear to have an effect on cerebrovascular outcomes, with the effect appearing even smaller than that for CVD outcomes. Consideration of apolipoprotein apolipoprotein(a) (apo (a)) isoforms and LPA genetics in relation to the simple assessment of Lp(a) concentration may enhance improving clinical practice in vascular medicine. We also describe recent advances in Lp(a) research (including therapies) and highlight areas where further research is needed such as the measurement of Lp(a) and its involvement in additional pathophysiological processes.
|Additional Information:||This is an Accepted Manuscript of an article published by Taylor & Francis in Critical Reviews in Clinical Laboratory Sciences on 1/11/16, available online: http://dx.doi.org/10.1080/10408363.2016.1188055|
|Uncontrolled Keywords:||11 Medical And Health Sciences|
|Subjects:||R Medicine > RM Therapeutics. Pharmacology
R Medicine > RS Pharmacy and materia medica
|Divisions:||Pharmacy & Biomolecular Sciences|
|Publisher:||Taylor & Francis|
|Date Deposited:||09 May 2016 10:05|
|Last Modified:||05 Dec 2016 12:33|
|DOI or Identification number:||10.1080/10408363.2016.1188055|
Actions (login required)